Christian Armando Laverde Cubides
Research Subjects
Christian Armando Laverde Cubides has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Juliana Palacio Varona
Universidad El Bosque
1 shared publication - María Alexandra Ángel Rodríguez
Universidad de La Sabana
1 shared publication - María Andrea Estévez-Flórez
Universidad El Bosque
1 shared publication
Latest Publications
- Open Access
- 2 July 2025
- Published by Universidad de La Salle in Ciencia y Tecnología para la Salud Visual y Ocular
- Vol. 23 (1) , e5642
Effectiveness of the use of anti-vegf in eyes with corneal neovascularization: A review of the literature
Purpose: To identify, through a scoping review of the literature, the evidence regarding the efficacy of vascular endothelial growth factor inhibitor treatment in corneal neovascularization. Materials and methods: A literature search was implemented in medical indexing databases: Medline (Pubmed), Web Of Science, Embase, and Scielo of articles in both English and Spanish, through the terms MesH and DeCs: "Corneal Neovascularization," "Cornea," "Ranibizumab", "Lucentis" and "Vascular Endothelial Growth Factor" in the last ten years (2013 - 2023). Results: 6,124 articles were initially found, which, after review and selection, resulted in a final sample of 37 articles, of which only 19 were clinical studies or case reports. The studies were conducted in both humans and animals. They reported results that included all types of vascular endothelial growth factor (anti-VEGF) inhibitors available on the market, applied in different routes of administration, and with some combinations of therapies. The causes of corneal neovascularization varied widely. Conclusion: No adverse events were reported in any study, and all studies documented a decrease in the percentage or area of corneal neovascularization (NV) regardless of etiology or route of administration, being more effective topically and at higher doses. The most effective drugs were bevacizumab and ranibizumab, but more evidence is needed with experimental clinical studies in humans.
- 2 July 2025
- Published by Universidad de La Salle in Ciencia y Tecnología para la Salud Visual y Ocular
- Vol. 23 (1) , e5642
Open AccessEffectiveness of the use of anti-vegf in eyes with corneal neovascularization: A review of the literature
Purpose: To identify, through a scoping review of the literature, the evidence regarding the efficacy of vascular endothelial growth factor inhibitor treatment in corneal neovascularization. Materials and methods: A literature search was implemented in medical indexing databases: Medline (Pubmed), Web Of Science, Embase, and Scielo of articles in both English and Spanish, through the terms MesH and DeCs: "Corneal Neovascularization," "Cornea," "Ranibizumab", "Lucentis" and "Vascular Endothelial Growth Factor" in the last ten years (2013 - 2023). Results: 6,124 articles were initially found, which, after review and selection, resulted in a final sample of 37 articles, of which only 19 were clinical studies or case reports. The studies were conducted in both humans and animals. They reported results that included all types of vascular endothelial growth factor (anti-VEGF) inhibitors available on the market, applied in different routes of administration, and with some combinations of therapies. The causes of corneal neovascularization varied widely. Conclusion: No adverse events were reported in any study, and all studies documented a decrease in the percentage or area of corneal neovascularization (NV) regardless of etiology or route of administration, being more effective topically and at higher doses. The most effective drugs were bevacizumab and ranibizumab, but more evidence is needed with experimental clinical studies in humans.